Introduction: This study reports the oncological outcome of a non-selected series of patients with human papillomavirus(HPV)-positive and -negative oropharyngeal squamous cell carcinoma (OSCC) preferentially managed with upfront surgery. Methods: Consecutive OSCC cases (n = 378) diagnosed from 2000 to 2010 in our department were evaluated for risk factors, HPV association, therapy and overall survival (OS). HPV status was determined by combined DNA and p16 testing, and treatment was defined as the first course of treatment with any kind of surgery (upfront surgery) or primary chemoradiotherapy. OS of HPV-associated and HPV-negative patients was compared using Kaplan-Meier and multivariable Cox regression analyses. Results: The majority of OSCC patients (215 of 361; 69.5%) received upfront surgery as first-line treatment in curative intent. The 5-year OS rate in patients with HPV-positive and HPV-negative tumors were 81.1 and 39.7%, respectively. Upfront surgery in HPV-negative (p < 0.001) and HPV-positive patients (p = 0.05) resulted in improved OS only in advanced stages. Multivariate analysis for patients revealed age in HPV-associated OSCC as an independent predictor for improved survival, and age, performance, N status and therapy as independent predictors in HPV-negative OSCC. Conclusions: Non-selected OSCC patients amenable to curative therapy show poor 5-year OS. The benefit of upfront surgery remains unclear. A younger patient age was the main factor for a better outcome in patients with HPV-associated OSCC.

Journal Section:
Original Article
Keywords:
Oropharyngeal cancer, Surgery, HPV, Prognosis, Head and neck cancer
1.
Simard EP, Torre LA, Jemal A: International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol 2014;50:387-403.
2.
Chaturvedi AK, Engels EA, Pfeiffer RM, et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-4301.
3.
Wittekindt C, Wagner S, Mayer CS, Klussmann JP: Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012;11:Doc09.
4.
Ang KK, Harris J, Wheeler R, et al.: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
5.
Howard J, Masterson L, Dwivedi RC, et al.: Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst Rev 2016;12:CD010963.
6.
Tassone P,Crawley M, Bovenzi C, et al.: Pathologic markers in surgically treated hpv-associated oropharyngeal cancer: retrospective study, systematic review, and meta-analysis. Ann Otol Rhinol Laryngol 2017;126:365-374.
7.
Hunter KU, Schipper M, Feng FY, et al.: Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys 2013;85:935-940.
8.
Ringash J, Fisher R, Peters L, et al.: Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: a substudy of randomized trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys 2017;97:678-686.
9.
Reuschenbach M, Tran T, Faulstich F, et al.: High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer 2011;104:1334-1341.
10.
Prigge ES, Urban K, Stiegler S, et al.: No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status. Hum Pathol 2014;45:2347-2354.
11.
Wittekindt C, Klussmann JP: Tumor staging and HPV-related oropharyngeal cancer. Recent Results Cancer Res 2017;206:123-133.
12.
Calais G, Alfonsi M, Bardet E, et al.: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
13.
Keane FK, Chen YH, Neville BA, et al.: Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer 2015;121:2594-2602.
14.
Guntinas-Lichius O, Wendt TG, Kornetzky N, et al.: Trends in epidemiology and treatment and outcome for head and neck cancer: a population-based long-term analysis from 1996 to 2011 of the Thuringian Cancer Registry. Oral Oncol 2014;50:1157-1164.
15.
Parsons JT, Mendenhall WM, Stringer SP, et al.: Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002;94:2967-2980.
16.
Denis F, Garaud P, Bardet E, et al.: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
17.
Gregoire V, Lefebvre JL, Licitra L, et al.: Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5): v184-186.
18.
Pfister DG, Spencer S, Brizel DM, et al.: Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014;12:1454-1487.
19.
Licitra L, Perrone F, Bossi P, et al.: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-5636.
20.
Fischer CA, Zlobec I, Green E, et al.: Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2010;126:1256-1262.
21.
Zenga J, Wilson M, Adkins DR, et al.: Treatment outcomes for T4 oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141:1118-1127.
22.
Kelly JR, Park HS, An Y, et al.: Comparison of survival outcomes among human papillomavirus-negative cT1-2 N1-2b patients with oropharyngeal squamous cell cancer treated with upfront surgery vs definitive chemoradiation therapy: an observational study. JAMA Oncol 2017;doi: 10.1001/jamaoncol.2016.5769.
23.
Diaz-Molina JP, Rodrigo JP, Alvarez-Marcos C, et al.: Functional and oncological results of non-surgical vs surgical treatment in squamous cell carcinomas of the oropharynx. Acta Otorrinolaringol Esp 2012;63:348-354.
24.
Karatzanis AD, Psychogios G, Mantsopoulos K, et al.: Management of advanced carcinoma of the base of tongue. J Surg Oncol 2012;106:713-718.
25.
Bossi P, Orlandi E, Miceli R, et al.: Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. Ann Oncol 2014;25:694-699.
26.
Hamilton D, Khan MK, Oʼhara J, Paleri V: The changing landscape of oropharyngeal cancer management. J Laryngol Otol 2017;131:3-7.
27.
Turner MT, Byrd JK, Ferris RL: Current role of surgery in the management of oropharyngeal cancer. J Oncol Pract 2016;12:1176-1183.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.